{'fraction_non_alphanumeric': 0.020802377414561663, 'fraction_numerical': 0.01337295690936107, 'mean_word_length': 5.236111111111111, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical eficacy of placentrex injection in pelvic inflammatory disease.

Combination of placentrex injection with antimicrobial therapy is a better option for treating pelvic inflammatory disease (PID) than only antimicrobial therapy; which also gives more sustained effect and lesser recurrences. Improvements in symptoms continue despite stopping therapy. Addition of placentrex leads to marked improvement in dyspareunia, less fornix tenderness and better uterine mobility suggesting better effect on adnexal tissues and parametrium. As placentrex decreases adnexal inflammation to significant level in comparison to antimicrobials alone, it can be a good option- specially to reduce the risk of tubal damage, infertility and formation of adnexal mass. In a study of 100 cases of PID, 50 in group I and II each; 42 in group 1 and 32 in group II completed the study. Marked reduction in various symptoms was observed in study group I (27-59%) where as in group II where only antimicrobial was given, reduction was found in range of 12-48%. Thus overall, group I had better as well as sustained effect of therapy on relieving dyspareunia, fornix tenderness and uterine restricted mobility which was statistically significant. In other symptoms and signs, there was marginal efficacy except in cervical erosion where no improvement was observed.